Literature DB >> 16205052

Bronchoscopic surfactant administration in pediatric patients with persistent lobar atelectasis.

Martin F Krause1, Philipp von Bismarck, Hans C Oppermann, Tobias Ankermann.   

Abstract

Persistent lobar atelectasis in pediatric patients on mechanical ventilation results in impaired gas exchange and lung mechanics and contributes to a further need for mechanical ventilation. The most common types of atelectasis in children are resorption atelectasis following airway obstruction, and atelectasis due to surfactant deficiency or dysfunction. We aimed to determine whether bronchoscopic suctioning and surfactant application to atelectatic lung segments would result in improved oxygenation, ventilation, chest X-ray scoring, and early extubation. Five children with heterogeneous lung diseases (aged between 7 months and 15 years) were treated with a diluted surfactant preparation (Curosurf) in a concentration of 5-10 mg/ml (total dose 120-240 mg) which was instilled into the affected segments. Outcome parameters were gas exchange, radiographic resolution of atelectasis and extubation. All mechanically ventilated patients could be extubated within 24 h following the intervention. Bronchoscopic surfactant application could be carried out without adverse effects and brought improvements in oxygenation, respiratory rate, and partial or complete resolution of atelectases without recurrence. (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16205052     DOI: 10.1159/000088713

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  3 in total

1.  [Prevention and treatment of atelectasis after thoracotomy for lung cancer].

Authors:  Yongbo Yang; Jun Chen; Daxing Zhu; Gang Chen; Zhigang Li; Mei Li; Sen Wei; Xiaoming Qiu; Honglin Zhao; Yi Liu; Qinghua Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-03

Review 2.  What's new in surfactant? A clinical view on recent developments in neonatology and paediatrics.

Authors:  Jasper V Been; Luc J I Zimmermann
Journal:  Eur J Pediatr       Date:  2007-05-22       Impact factor: 3.183

Review 3.  Rational use of mucoactive medications to treat pediatric airway disease.

Authors:  R S N Linssen; J Ma; R A Bem; B K Rubin
Journal:  Paediatr Respir Rev       Date:  2020-06-16       Impact factor: 2.726

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.